Citations (71)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Rossana Maffei, Stefania Fiorcari, Silvia Martinelli, Stefania Benatti, Jenny Bulgarelli, Lara Rizzotto, Giulia Debbia, Rita Santachiara, Gian Matteo Rigolin, Francesco Forconi, Davide Rossi, Luca Laurenti, Giuseppe A. Palumbo, Daniele Vallisa, Antonio Cuneo, Gianluca Gaidano, Mario Luppi & Roberto Marasca. (2018) Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. Leukemia & Lymphoma 59:2, pages 423-433.
Read now
Read now
Francesca R. Mauro, Angelo M. Carella, Stefano Molica, Francesca Paoloni, Anna M. Liberati, Francesco Zaja, Valeria Belsito, Agostino Cortellezzi, Rita Rizzi, Patrizia Tosi, Mauro Spriano, Antonietta Ferretti, Mauro Nanni, Marilisa Marinelli, Maria S. De Propris, Sonia M. Orlando, Marco Vignetti, Antonio Cuneo, Anna R. Guarini & Robin Foà. (2017) Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial. Leukemia & Lymphoma 58:7, pages 1640-1647.
Read now
Read now
Gilad Itchaki & Jennifer R. Brown. (2017) Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 26:5, pages 633-650.
Read now
Read now
Punit L. Jain, Carrie Anne Orlikowski & Alessandra Ferrajoli. (2016) Lenalidomide in chronic lymphocytic leukemia. Expert Opinion on Orphan Drugs 4:9, pages 971-980.
Read now
Read now
Clemens M. Wendtner, Michael Hallek, Graeme A. M. Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Dürig, Matt Kalaycio, John G. Gribben, Stephan Stilgenbauer, Andreas Buhler, Thomas J. Kipps, Brendan Purse, Jennie Zhang, Sabine De Bedout, Jay Mei & Asher Chanan-Khan. (2016) Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. Leukemia & Lymphoma 57:6, pages 1291-1299.
Read now
Read now
Ayse Salihoglu, Muhlis Cem Ar & Teoman Soysal. (2015) Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide. Expert Review of Hematology 8:6, pages 765-783.
Read now
Read now
Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2015) Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs 20:3, pages 423-447.
Read now
Read now
Nadine Kutsch, Michael Hallek & Barbara Eichhorst. (2015) Emerging therapies for refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 56:2, pages 285-292.
Read now
Read now
Michaela Semeraro, Erika Vacchelli, Alexander Eggermont , Jerome Galon, L Zitvogel, G Kroemer & Lorenzo Galluzzi. (2013) Trial Watch: Lenalidomide-based immunochemotherapy. OncoImmunology 2:11.
Read now
Read now
Peter H Wiernik. (2013)
Lenalidomide in lymphomas and chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 14:4, pages 475-488.
Read now
Read now
Aisha Masood, Taimur Sher, Aneel Paulus, Kena C Miller, Kasyapa S Chitta & Asher Chanan-Khan. (2011) Targeted treatment for chronic lymphocytic leukemia. OncoTargets and Therapy 4, pages 169-183.
Read now
Read now
Clive S. Zent & Neil E. Kay. (2011) Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leukemia & Lymphoma 52:8, pages 1425-1434.
Read now
Read now
Regina Pileckyte, Mindaugas Jurgutis, Vilma Valceckiene, Mindaugas Stoskus, Egle Gineikiene, Jurgita Sejoniene, Andrius Degulys, Tadas Zvirblis & Laimonas Griskevicius. (2011) Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leukemia & Lymphoma 52:6, pages 1055-1065.
Read now
Read now
Chadi Nabhan, Neil Dalal, Jayesh Mehta & Neil E. Kay. (2011) Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. Leukemia & Lymphoma 52:3, pages 374-386.
Read now
Read now
Massimo Gentile, Anna Grazia Recchia, Ernesto Vigna, Carla Mazzone, Eugenio Lucia, Vincenzo Gigliotti, Sabrina Bossio, Antonio Madeo, Lucio Morabito, Pasquale Servillo, Stefania Franzese, Nadia Caruso, Laura De Stefano, Maria Grazia Bisconte, Carlo Gentile & Fortunato Morabito. (2011) Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 20:2, pages 273-286.
Read now
Read now
Jennifer R. Brown. (2010) Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?. Leukemia & Lymphoma 51:8, pages 1382-1385.
Read now
Read now
Ali Bazargan & Constantine S. Tam. (2010) New agents for the treatment of genetically high-risk chronic lymphocytic leukemia. Leukemia & Lymphoma 51:1, pages 3-4.
Read now
Read now
Articles from other publishers (54)
Michael Hallek & Othman Al‐Sawaf. (2021) Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. American Journal of Hematology 96:12, pages 1679-1705.
Crossref
Crossref
Isaac Park, Tra Mi Phan & Jing Fang. (2021) Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q. Cancers 13:20, pages 5084.
Crossref
Crossref
A. A. Danilenko, S. V. Shakhtarina & N. A. Falaleeva. (2020) MODERN APPROACHES TO TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA. Siberian journal of oncology 19:6, pages 106-118.
Crossref
Crossref
Martina Maďarová, Dominik Dobransky & Tomas Dobransky. 2019. Advances in Hematologic Malignancies. Advances in Hematologic Malignancies.
Michael Hallek. (2019) Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. American Journal of Hematology 94:11, pages 1266-1287.
Crossref
Crossref
Mónica Villa-Álvarez, Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ana P. Gonzalez-Rodriguez, Angel R. Payer, Esther Gonzalez-Garcia, María C. Villa-Álvarez, Alejandro López-Soto & Segundo Gonzalez. (2018) Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia. Frontiers in Immunology 9.
Crossref
Crossref
Michael Hallek. (2017) Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. American Journal of Hematology 92:9, pages 946-965.
Crossref
Crossref
Tanya Siddiqi & Steven T. Rosen. 2017. Management of Lymphomas: A Case-Based Approach. Management of Lymphomas: A Case-Based Approach
47
73
.
Celso Arrais Rodrigues, Matheus Vescovi Gonçalves, Maura Rosane Valério Ikoma, Irene Lorand-Metze, André Domingues Pereira, Danielle Leão Cordeiro de Farias, Maria de Lourdes Lopes Ferrari Chauffaille, Rony Schaffel, Eduardo Flávio Oliveira Ribeiro, Talita Silveira da Rocha, Valeria Buccheri, Yuri Vasconcelos, Vera Lúcia de Piratininga Figueiredo, Carlos Sérgio Chiattone & Mihoko Yamamoto. (2016) Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. Revista Brasileira de Hematologia e Hemoterapia 38:4, pages 346-357.
Crossref
Crossref
Liang Liang, Ming Zhao, Yuan-chao Zhu, Xin Hu, Li-ping Yang & Hui Liu. (2016) Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis. Annals of Hematology 95:9, pages 1473-1482.
Crossref
Crossref
Julio C. Chavez, Miguel Piris-Villaespesa, Samir Dalia, John Powers, Elyce Turba, Lisa Nodzon, Rami Komrokji, Lubomir Sokol, Frederick L. Locke, Jeffrey Lancet, Eduardo M. Sotomayor, Mohamed A. Kharfan-Dabaja & Javier Pinilla-Ibarz. (2016) Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leukemia Research 47, pages 78-83.
Crossref
Crossref
A Bühler, C-M Wendtner, T J Kipps, L Rassenti, G A M Fraser, A-S Michallet, P Hillmen, J Dürig, S A Gregory, M Kalaycio, T Aurran-Schleinitz, L Trentin, J G Gribben, A Chanan-Khan, B Purse, J Zhang, S De Bedout, J Mei, M Hallek & S Stilgenbauer. (2016) Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer Journal 6:3, pages e404-e404.
Crossref
Crossref
Ciara L. Freeman & John G. Gribben. (2016) Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). Current Hematologic Malignancy Reports 11:1, pages 29-36.
Crossref
Crossref
Rossana Maffei, Elisabetta Colaci, Stefania Fiorcari, Silvia Martinelli, Leonardo Potenza, Mario Luppi & Roberto Marasca. (2016) Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology 97, pages 291-302.
Crossref
Crossref
Michael Hallek. (2015) Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. American Journal of Hematology 90:5, pages 446-460.
Crossref
Crossref
Lohith S Bachegowda & Stefan K Barta. (2014) Genetic and molecular targets in lymphoma: implications for prognosis and treatment. Future Oncology 10:15, pages 2509-2528.
Crossref
Crossref
Jessie-F. Fecteau, Laura G. Corral, Emanuela M. Ghia, Svetlana Gaidarova, Diahnn Futalan, Ila Sri Bharati, Brian Cathers, Maria Schwaederlé, Bing Cui, Antonia Lopez-Girona, Davorka Messmer & Thomas J. Kipps. (2014) Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53. Blood 124:10, pages 1637-1644.
Crossref
Crossref
Danelle F. JamesLillian WernerJennifer R. BrownWilliam G. WierdaJacqueline C. BarrientosJanuario E. CastroAndrew GreavesAmy J. JohnsonLaura Z. RassentiKanti R. RaiDonna NeubergThomas J. Kipps. (2014) Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium. Journal of Clinical Oncology 32:19, pages 2067-2073.
Crossref
Crossref
Christian P. Pallasch & Michael Hallek. (2014) Incorporating Targeted Agents Into Future Therapy of Chronic Lymphocytic Leukemia. Seminars in Hematology 51:3, pages 235-248.
Crossref
Crossref
Tadeusz Robak. (2014) New horizons in the treatment of chronic lymphocytic leukemia. Acta Haematologica Polonica 45:2, pages 122-131.
Crossref
Crossref
Rossana Maffei, Stefania Fiorcari, Jenny Bulgarelli, Lara Rizzotto, Silvia Martinelli, Gian Matteo Rigolin, Giulia Debbia, Ilaria Castelli, Goretta Bonacorsi, Rita Santachiara, Francesco Forconi, Davide Rossi, Luca Laurenti, Giuseppe A. Palumbo, Daniele Vallisa, Antonio Cuneo, Gianluca Gaidano, Mario Luppi & Roberto Marasca. (2014) Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Experimental Hematology 42:2, pages 126-136.e1.
Crossref
Crossref
Andrea Acebes-Huerta, Leticia Huergo-Zapico, Ana Pilar Gonzalez-Rodriguez, Azahara Fernandez-Guizan, Angel R. Payer, Alejandro L?pez-Soto & Segundo Gonzalez. (2014) Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells. BioMed Research International 2014, pages 1-11.
Crossref
Crossref
John C. Byrd & Joseph M. Flynn. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1958
1978.e7
.
Katja Weisel & Lothar Kanz. 2014. Small Molecules in Oncology. Small Molecules in Oncology
347
357
.
Michael Hallek. (2013) Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematology 2013:1, pages 138-150.
Crossref
Crossref
Michael Hallek. (2013) Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 122:23, pages 3723-3734.
Crossref
Crossref
Michael Hallek. (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. American Journal of Hematology 88:9, pages 803-816.
Crossref
Crossref
Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C. Badoux, Steliana Calin, James M. Reuben, Susan O’Brien, Steven M. Kornblau, Hagop M. Kantarjian, Hui Gao & Alessandra Ferrajoli. (2013) Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 122:5, pages 734-737.
Crossref
Crossref
Chiara Lobetti-Bodoni, Francesco Bertoni, Georg Stussi, Franco Cavalli & Emanuele Zucca. (2013) The changing paradigm of chronic lymphocytic leukemia management. European Journal of Internal Medicine 24:5, pages 401-410.
Crossref
Crossref
Francesco Spina, Francesca Rezzonico, Lucia Farina & Paolo Corradini. (2013) Long‐term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. European Journal of Haematology 90:4, pages 340-344.
Crossref
Crossref
Andrea Schnaiter & Stephan Stilgenbauer. (2013) 17p Deletion in Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America 27:2, pages 289-301.
Crossref
Crossref
John C. Riches & John G. Gribben. (2013) Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America 27:2, pages 207-235.
Crossref
Crossref
Carlo Visco, Silvia Finotto, Fabrizio Pomponi, Roberto Sartori, Francesco Laveder, Livio Trentin, Rossella Paolini, Eros Di Bona, Marco Ruggeri & Francesco Rodeghiero. (2013) The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic leukemia. American Journal of Hematology 88:4, pages 289-293.
Crossref
Crossref
Christine I. Chen. (2012) Lenalidomide Alone and in Combination for Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports 8:1, pages 7-13.
Crossref
Crossref
Xavier C. BadouxMichael J. KeatingSijin WenWilliam G. WierdaSusan M. O'BrienStefan FaderlRachel SargentJan A. BurgerAlessandra Ferrajoli. (2013) Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 31:5, pages 584-591.
Crossref
Crossref
Ana Pilar Gonz?lez-Rodr?guez, Angel R. Payer, Andrea Acebes-Huerta, Leticia Huergo-Zapico, Monica Villa-Alvarez, Esther Gonzalez-Garc?a & Segundo Gonzalez. (2013) Lenalidomide and Chronic Lymphocytic Leukemia. BioMed Research International 2013, pages 1-9.
Crossref
Crossref
Alexander L. Ruchelman, Hon-Wah Man, Weihong Zhang, Roger Chen, Lori Capone, Jian Kang, Anastasia Parton, Laura Corral, Peter H. Schafer, Darius Babusis, Mehran F. Moghaddam, Yang Tang, Michael A. Shirley & George W. Muller. (2013) Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity. Bioorganic & Medicinal Chemistry Letters 23:1, pages 360-365.
Crossref
Crossref
Maria Joao Baptista, Ana Muntañola, Eva Calpe, Pau Abrisqueta, Olga Salamero, Eva Fernández, Carles Codony, Eva Giné, Susana G. Kalko, Marta Crespo & Francesc Bosch. (2012) Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status. Clinical Cancer Research 18:21, pages 5924-5933.
Crossref
Crossref
Beiqing Pan & Suzanne Lentzsch. (2012) The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacology & Therapeutics 136:1, pages 56-68.
Crossref
Crossref
Maria Cosenza, Monica Civallero, Giulia Grisendi, Luigi Marcheselli, Erika Roat, Alessia Bari & Stefano Sacchi. (2012) Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines. Annals of Hematology 91:10, pages 1613-1622.
Crossref
Crossref
Cynthia L. Toze, Chinmay B. Dalal, Thomas J. Nevill, Tanya L. Gillan, Yasser R. Abou Mourad, Michael J. Barnett, Raewyn C. Broady, Donna L. Forrest, Donna E. Hogge, Stephen H. Nantel, Maryse M. Power, Kevin W. Song, Heather J. Sutherland, Clayton A. Smith, Sujaatha Narayanan, Sean S. Young, Joseph M. Connors & John D. Shepherd. (2012) Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. British Journal of Haematology 158:2, pages 174-185.
Crossref
Crossref
Estrella CarballidoMarays VelizRami KomrokjiJavier Pinilla-Ibarz. (2012) Immunomodulatory Drugs and Active Immunotherapy for Chronic Lymphocytic Leukemia. Cancer Control 19:1, pages 54-67.
Crossref
Crossref
Agostino Cortelezzi, Mariarita Sciumè & Gianluigi Reda. (2012) Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia. Advances in Hematology 2012, pages 1-7.
Crossref
Crossref
Jennifer R. Brown. (2011) The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia. Hematology 2011:1, pages 110-118.
Crossref
Crossref
Asher A. Chanan-Khan, Kasyapa Chitta, Noreen Ersing, Aneel Paulus, Aisha Masood, Taimur Sher, Abhisek Swaika, Paul K. Wallace, Terry L. MashtareJrJr, Greg Wilding, Kelvin Lee, Myron S. Czuczman, Ivan Borrello & Naveen Bangia. (2011) Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. British Journal of Haematology 155:4, pages 457-467.
Crossref
Crossref
C. Patrick Reynolds, Min H. Kang, Stephen T. Keir, Richard Gorlick, E. Anders Kolb, Richard Lock, John M. Maris, Hernan Carol, Christopher L. Morton, Catherine A. Billups, Malcolm A. Smith & Peter J. Houghton. (2011) Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatric Blood & Cancer 57:4, pages 606-611.
Crossref
Crossref
R G Wickremasinghe, A G Prentice & A J Steele. (2011) p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia 25:9, pages 1400-1407.
Crossref
Crossref
Bang‐Ning Lee, Hui Gao, Evan N. Cohen, Xavier Badoux, William G. Wierda, Zeev Estrov, Stefan H. Faderl, Michael J. Keating, Alessandra Ferrajoli & James M. Reuben. (2011) Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 117:17, pages 3999-4008.
Crossref
Crossref
Saman Hewamana & Claire Dearden. (2011) Treatment options for high-risk chronic lymphocytic leukaemia. Therapeutic Advances in Hematology 2:3, pages 147-159.
Crossref
Crossref
Davide RossiValeria SpinaClara DeambrogiSilvia RasiLuca LaurentiKostas StamatopoulosLuca Arcaini, Marco LucioniGabrielle B. RocqueZijun Y. Xu-MonetteCarlo ViscoJulie ChangEkaterina ChigrinovaFrancesco ForconiRoberto MarascaCaroline BessonTheodora PapadakiMarco PaulliLuigi M. LaroccaStefano A. PileriValter Gattei, Francesco BertoniRobin Foà, Ken H. YoungGianluca Gaidano. (2011) The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 117:12, pages 3391-3401.
Crossref
Crossref
Jerome B. Zeldis, Robert Knight, Mohamad Hussein, Rajesh Chopra & George Muller. (2011) A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Annals of the New York Academy of Sciences 1222:1, pages 76-82.
Crossref
Crossref
Sameer A. Batoo & Francisco Hernandez-Ilizaliturri. (2010) The emerging role of lenalidomide in the management of lymphoid malignancies. Therapeutic Advances in Hematology 2:1, pages 45-53.
Crossref
Crossref
N. Zojer & H. Ludwig. (2010) Chronic lymphocytic leukaemia – emerging treatment options: a report from the ASH Meeting 2009. memo - Magazine of European Medical Oncology 3:2, pages 65-68.
Crossref
Crossref
Judith Moser. (2010) Hämatologische Neoplasien: Therapie im Wandel. Wiener klinisches Magazin 13:3, pages 51-51.
Crossref
Crossref